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Objective: Insulin resistance has been linked to development and progression of atherosclerosis and
is present in most patients with type 2 diabetes. Whether the degree of insulin resistance predicts
adverse outcomes in patients with type 2 diabetes and acute coronary syndrome (ACS) is uncertain.
Design: The Effect of Aleglitazar on Cardiovascular Outcomes after Acute Coronary Syndrome in
Patients with Type 2 Diabetes Mellitus trial compared the peroxisome proliferator-activated
receptor-a/g agonist aleglitazar with placebo in patients with type 2 diabetes and recent ACS.
In participants not treated with insulin, we determined whether baseline homeostasis model
assessment of insulin resistance (HOMA-IR; n = 4303) or the change in HOMA-IR on assigned
study treatment (n = 3568) was related to the risk of death or major adverse cardiovascular events
(cardiovascular death, myocardial infarction, and stroke) in unadjusted and adjusted models.
Because an inverse association of HOMA-IR with N-terminal pro-B-type natriuretic peptide (NT-
proBNP) has been described, we specifically examined effects of adjustment for the latter.
Results: In unadjusted analysis, twofold higher baseline HOMA-IR was associated with lower risk
of death [hazard ratio (HR): 0.79, 95% CI: 0.68 to 0.91, P = 0.002]. Adjustment for 24 standard
demographic and clinical variables had minimal effect on this association. However, after further
adjustment for NT-proBNP, the association of HOMA-IR with death was no longer present (adjusted
HR: 0.99, 95% CI: 0.83 to 1.19, P = 0.94). Baseline HOMA-IR was not associated with major adverse
cardiovascular events, nor was the change in HOMA-IR on study treatment associated with death or
major adverse cardiovascular events.
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Abbreviations: ACS, acute coronary syndrome; AleCardio, Effect of Aleglitazar on
Cardiovascular Outcomes after Acute Coronary Syndrome in Patients with Type 2 Di-
abetes Mellitus; eGFR, estimated glomerular filtration rate; HOMA2-B, updated ho-
meostasis model assessment of b cell function; HOMA2-IR, updated homeostasis model
assessment of insulin resistance; HOMA-IR, homeostasis model assessment of insulin
resistance; HR, hazard ratio; hs-CRP, high-sensitivity C-reactive protein; IQR,
interquartile range; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PPAR, per-
oxisome proliferator-activated receptor.
Conclusions:After accounting for levels of NT-proBNP, insulin resistance assessed by HOMA-IR is not
related to the risk of death or major adverse cardiovascular events in patients with type 2 diabetes
and ACS. (J Clin Endocrinol Metab 103: 2522–2533, 2018)
Insulin resistance is present in most patients with type 2diabetes and has been related to the development and
accelerated progression of atherosclerosis, the vulnera-
bility of coronary plaques to rupture and thrombosis (1,
2), and the risk of adverse outcomes after coronary re-
vascularization (3, 4). Patients with acute coronary
syndrome (ACS) and type 2 diabetes are at particularly
high risk for recurrent ischemic events (5–7). It is un-
known whether the degree of insulin resistance predicts
subsequent risk among patients with type 2 diabetes and
ACS.
The homeostasis model assessment of insulin resis-
tance (HOMA-IR) is a simple, although imperfect, index
of insulin resistance that is derived from measurements
of fasting plasma glucose and insulin (8, 9). Elevated
HOMA-IR has been associated with an increased risk of
cardiovascular events in nondiabetic patients, both in
primary and secondary prevention (10–13). However,
there is conflicting evidence for a relation of HOMA-IR
to cardiovascular risk among patients with established
type 2 diabetes. In the Verona Diabetes Complications
Study and the Veterans Affairs High-Density Lipoprotein
Intervention Trial, HOMA-IR was related to an increased
risk of future cardiovascular events (11, 14). Conversely,
an association between HOMA-IR and cardiovascular
risk was not observed in the UK Prospective Diabetes
Study (15).
Complicating the interpretation of these data, other
studies have found an inverse association of HOMA-IR
with levels of N-terminal pro-B-type natriuretic peptide
(NT-proBNP) (16–18), and a direct association of NT-
proBNP with mortality and cardiovascular events (19,
20). Thus, NT-proBNP levels could confound an asso-
ciation of HOMA-IR with outcomes.
Agonists of peroxisome proliferator-activated
receptor (PPAR)-g increase insulin sensitivity and
therefore lower HOMA-IR in patients with insulin re-
sistance. The Effect of Aleglitazar on Cardiovascular
Outcomes after Acute Coronary Syndrome in Patients
with Type 2 Diabetes Mellitus (AleCardio) trial com-
pared aleglitazar, a dual agonist of PPAR-a and -g, with
placebo in patients with type 2 diabetes and recent ACS.
Aleglitazar did not affect the risk of cardiovascular
events (21).
To gain insight into the relationship between insulin
resistance and outcomes after ACS in patients with type 2
diabetes, we examined data from the AleCardio trial to
determine associations of baselineHOMA-IR, or the change
in HOMA-IR on assigned study treatment, with death
and major adverse cardiovascular events. Because an in-
verse relationship of HOMA-IR with levels of natriuretic
peptides has been described (16–18), we specifically ex-
aminedwhether associations ofHOMA-IRwith outcomes
were influenced by levels of NT-proBNP.
Materials and Methods
Study design
The current report is a post-analysis of the AleCardio trial
(ClinicalTrials.gov no. NCT01042769). The design and prin-
cipal results of the trial have been described previously (21, 22).
The protocol was approved by institutional review boards,
written informed consent was obtained from all participants,
and the study was conducted in full conformance with the
principles of the Declaration of Helsinki and in accordance with
local law and regulations.
AleCardio compared the efficacy and safety of aleglitazar
(F. Hoffmann-La Roche Ltd, Basel, Switzerland) with pla-
cebo in patients with established or newly diagnosed type 2
diabetes and recent ACS including unstable angina, non-ST
segment elevation myocardial infarction, and ST segment
elevation myocardial infarction. A total of 7226 patients at
720 sites in 26 countries on 5 continents were enrolled.
Patients with symptomatic heart failure or hospitalization
with a primary diagnosis of heart failure within the previous
12 months were excluded. Other exclusion criteria included
severe peripheral edema, an estimated glomerular filtration
rate (eGFR) less than 45 mL/min/1.73 m2, or treatment with
another PPAR agonist. Evidence-based use of cardiovascular
medications and coronary revascularization procedures was
recommended for all participants. Patients were randomly
assigned in a double-blind fashion to receive aleglitazar (150mg/d)
or matching placebo in a 1:1 ratio. Randomization occurred
during an interval beginning at hospital discharge and extending
until 12 weeks after the index ACS event. Fasting glucose and
insulin were measured in all participants at randomization
(baseline values). However, the use of exogenous insulin in-
fluences the value of HOMA-IR. Therefore, the present
analysis included 4303 participants (2159 patients in the
aleglitazar group and 2144 patients in the placebo group)
with a baseline measurement of fasting insulin and glucose
who were not treated with insulin at that time. Analysis of the
change in HOMA-IR from baseline to 3 months later was
performed in a subset of 3568 patients (1801 patients in the
aleglitazar group and 1767 patients in the placebo group) who
had pairedmeasurements of fasting insulin and glucose at both
time points and were not treated with exogenous insulin be-
tween those times.
HOMA-IR models
At baseline and 3 months later, blood samples were col-
lected after an overnight fast of at least 8 hours. The original
HOMA1-IR was calculated as (8):
HOMA1-IR ¼
fasting plasma glucose½mmol=L$fasting plasma insulin ½mU=mL
22:5
The updated homeostasis model assessment of insulin resistance
(HOMA2-IR) and updated homeostasis model assessment of
b cell function (HOMA2-B) were also calculated using the
online HOMA calculator version 2.2.3 for specific insulin
available atwww.dtu.ox.ac.uk/homacalculator (23). TheHOMA2-
IR and HOMA2-B models include fasting glucose and insulin
levels in a defined steady-state condition (fasting glucose: 3 to
25 mmol/L and fasting insulin: 20 to 300 pmol/L); patients
with levels outside these limits were excluded (baseline HOMA2-
IR and HOMA2-B: n = 3999, 99.9%; change in HOMA2-
IR and HOMA2-B from baseline to month 3: n = 3564,
99.9%) (23).
Plasma glucose was measured with the Roche Cobas Ana-
lyzer and GLUC3 reagent kit (Roche Diagnostics, Indianapolis,
IN), with an intra-assay precision of 0.8% to 1.1% coefficient
of variation and an interassay precision of 1.1% to 1.3% co-
efficient of variation. Insulin was measured by the immuno-
enzymatic Access Ultrasensitive Insulin Assay (Beckman Coulter
Inc., Brea, CA), with an intra-assay precision of 2.0% to 4.2%
coefficient of variation and an interassay precision of #7%
coefficient of variation.
Endpoints
We examined relationships of baseline HOMA1-IR with all-
cause death, cardiovascular death (a secondary outcomemeasure
in the parent trial), and major cardiovascular events (cardio-
vascular death, nonfatal myocardial infarction, or nonfatal stroke;
the primary outcome measure in the parent trial). We also ex-
amined the relationship of the change in HOMA1-IR from
baseline to 3 months to the risk of the outcome events after
3 months. Sensitivity analyses were performed using HOMA2-IR,
excluding patients on sulfonylureas, and assessing aleglitazar
and placebo groups separately.
Statistical analysis
Continuous variables are presented as mean6 SD or median
with interquartile range (IQR), as appropriate. HOMA-IR was
described as a continuous variable and by quartiles. The dis-
tribution of HOMA-IR was skewed, and therefore log2 trans-
formation was applied for further analysis. Differences among
quartiles of HOMA-IR were compared with analysis of variance
or the Kruskal-Wallis test for continuous variables, and with
x2 test for categorical variables.
We used Cox proportional hazard regression models strati-
fied by ACS index event (unstable angina, non-ST segment el-
evation myocardial infarction/ST segment elevation myocardial
infarction) and presence/absence of reperfusion therapy to
evaluate the association of each doubling inHOMA-IRwith the
endpoints. Unadjusted and two adjusted models were exam-
ined. Model 1 was adjusted for the following predefined var-
iables: age, sex, race, body mass index, smoking, hypertension,
prior coronary artery disease, prior congestive heart failure,
duration of diabetes prior to randomization, time from ACS
index event to randomization, glycated hemoglobin, log2 high-
sensitivity C-reactive protein (hs-CRP), log2 eGFR using the
Modification of Diet in Renal Disease equation, low-density
lipoprotein cholesterol, high-density lipoprotein cholesterol,
log2 triglycerides, and treatment with biguanides, sulfonylureas,
incretins, statins, beta-blockers, renin angiotensin blockers,
calcium channel blockers, and either aleglitazar or placebo.
Model 2 was adjusted for all of the above variables plus log2
NT-proBNP. Cox proportional hazards regression test of in-
teraction (HOMA-IR by treatment assignment) was used to
assess whether there was a differential effect of HOMA-IR by
treatment assignment on the endpoints. In the same fashion,
we used the Coxmodel to evaluate the association of the change
in HOMA-IR from baseline to month 3 (difference between
log2-transformed baseline and log2-transformed month 3 values)
with each of the same endpoints occurring after 3 months.
All testing was two sided and conducted at the 0.05 signif-
icance level. All statistical analyses were performed using SAS
version 9.4 (SAS Institute, Cary, NC).
Results
Baseline characteristics
At baseline, HOMA1-IR was 2.8 (1.7, 4.5) [median
(IQR)]. Patient characteristics by quartile of HOMA1-IR
are shown inTable 1. Comparedwith patients in the lower
quartiles of HOMA1-IR, patients in the higher quartiles
were younger, more likely to be white, and less likely to
be Asian. They also had a shorter antecedent duration of
diabetes, weremore likely to have a history of hypertension,
dyslipidemia, prior myocardial infarction, or coronary re-
vascularization, and were less likely to have presented with
ST segment elevation myocardial infarction as the index
ACS event.
Across quartiles of HOMA1-IR, most patients were
treated with aspirin, other antiplatelet agents, statins, and
biguanides. Patients in the higher quartiles of HOMA1-
IR were somewhat more likely to be treated with renin-
angiotensin system inhibitors, beta-blockers, and diuretics.
Very few patients in AleCardio were treated with glucagon-
like peptide-1 agonists or dipeptidyl peptidase-4 antagonists,
and none were treated with sodium-glucose cotransporter
2 antagonists.
As expected, patients in higher HOMA1-IR quartiles
were characterized by higher levels of glucose, insulin,
glycated hemoglobin, and triglycerides and lower levels
of high-density lipoprotein cholesterol. Progressive quar-
tiles of HOMA1-IRwere also associatedwith higher levels
of hemoglobin and hs-CRP, but with lower levels of NT-
proBNP. Mean NT-proBNP in quartile 1 of HOMA1-IR
was 2.36 times higher than in quartile 4 of HOMA1-IR
(Table 1).
In the placebo group, HOMA1-IR increased slightly
from baseline to month 3 by 0.13 (–0.77, 1.14) [median
(IQR); P , 0.001 vs baseline]. In contrast, aleglitazar
demonstrated the expected effects of a PPAR-g activator
by reducing HOMA1-IR during this period, by –0.94
(–2.14, –0.16) (P , 0.001 vs baseline, Table 2).
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0.89,P = 0.002). Additional adjustment forNT-proBNP in
model 2 neutralized the association of HOMA1-IR with
hospitalization for heart failure (adjusted HR: 0.93, 95%
CI: 0.75 to 1.15, P = 0.49).
Hypoglycemia and serious hypoglycemia occurred in
425 (9.9%) and 26 (0.6%) patients. Hypoglycemia did not
differ among HOMA1-IR quartiles [Q1: 97 (9.0%) pa-
tients, Q2: 105 (9.8%) patients, Q3: 107 (9.9%) patients,
and Q4: 116 (10.8%) patients, P = 0.58]. Similar results
were observed for serious hypoglycemia [Q1: 8 (0.7%)
patients, Q2: 8 (0.7%) patients, Q3: 5 (0.5%) patients, and
Q4: 5 (0.5%) patients, P = 0.71].
Changes inHOMA1-IR from baseline tomonth 3 were
not related to outcomes (Table 3). There was no inter-
action of treatment assignment and the change in
HOMA1-IR from baseline to month 3 on the risk of any
of the clinical outcomes.
In a sensitivity analysis, associations betweenHOMA2-
IR and outcomes were analyzed. The results were similar
to those obtained with HOMA1-IR. In unadjusted anal-
ysis, HOMA2-IR was significantly related with all-cause
and cardiovascular death; however, relations were atten-
uated after adjustment for the variables in model 1 and
neutralized after adjustment for the variables in model 2
(Table 3). In unadjusted analysis, HOMA2-B was signifi-
cantly associatedwith all-cause death, with trends observed
for cardiovascular death. Associations with all-cause death
were mitigated after multivariable adjustment (Table 3).
Findings were further confirmed in a sensitivity analysis
that excluded patients treated with sulfonylureas at base-
line (Supplemental Table 1). When analyzing the placebo
and aleglitazar groups separately, neither HOMA1-IR nor
HOMA2-IR was related with endpoints in adjusted anal-
ysis (Supplemental Table 2).
Associations of NT-proBNP with endpoints
In unadjusted analysis, a twofold higher baseline level of
NT-proBNPwas significantly associatedwith a higher risk of
all-cause death (HR: 1.65, 95%CI: 1.51 to 1.81,P,0.001),
cardiovascular death (HR: 1.76, 95% CI: 1.58 to 1.95, P,
0.001), nonfatal myocardial infarction (HR: 1.17, 95% CI:
1.09 to 1.26, P , 0.001), nonfatal stroke (HR: 1.24, 95%
CI: 1.06 to 1.46,P=0.008), andmajor cardiovascular events
(HR: 1.31, 95% CI: 1.24 to 1.39, P , 0.001). All associ-
ations remained significant after multivariable adjustments.
Changes in NT-proBNP from baseline to month 3 were
independently related to all-cause death, cardiovascular
death, and major adverse cardiovascular events (Table 4).
Discussion
This study shows that the degree of insulin resistance, as
reflected byHOMA-IR, does not independently determine
Associations of HOMA-IR with endpoints
Table 3 shows the unadjusted and adjusted risk of 
adverse events at the median (IQR) follow-up of 106 
(82, 129) weeks. All-cause death occurred in 152 patients 
(3.5%). Kaplan-Meier estimates of survival by quar-
tile of baseline HOMA1-IR are shown in Fig. 1. In un-
adjusted analysis, a twofold higher baseline level of 
HOMA1-IR was associated with a lower risk of all-cause 
death [hazard ratio (HR): 0.79, 95% CI: 0.68 to 0.91, 
P = 0.002]. The inverse relation of baseline HOMA1-IR 
with death was  due to an inverse  association with log  
insulin with death (HR: 0.74, 95% CI: 0.62 to 0.87, 
P = 0.0004), without an association of log2 glucose with 
death (HR: 0.98, 95% CI: 0.68 to 1.40, P = 0.90). Ad-
justment for the variables in model 1 had a minor effect 
on the association of HOMA1-IR with all-cause death 
(adjusted HR: 0.82, 95% CI: 0.69 to 0.98, P = 0.03). 
However, additional adjustment for NT-proBNP in model 
2 neutralized the association of HOMA1-IR with all-
cause death (adjusted HR: 0.99, 95% CI: 0.83 to 1.19, 
P = 0.94).
Cardiovascular death occurred in 110 patients (2.6%). A 
twofold higher baseline level of HOMA1-IR was associated 
with a lower risk of cardiovascular death in unadjusted 
analysis (HR: 0.82, 95% CI: 0.68 to 0.97, P = 0.02). The 
relation of baseline HOMA1-IR with cardiovascular death 
was also driven by an inverse association with log2 insulin 
(HR: 0.75, 95% CI: 0.62 to 0.92, P , 0.001) without 
association with log2 glucose (HR: 1.09, 95% CI: 0.72 to 
1.65, P = 0.69). The association of HOMA1-IR with 
cardiovascular death was attenuated after adjustment for 
the variables in model 1 (adjusted HR: 0.83, 95% CI: 0.68 
to 1.02, P = 0.07) and neutralized after additional ad-
justment for NT-proBNP in model 2 (adjusted HR: 1.05, 
95% CI: 0.85 to 1.29, P = 0.66). There was no interaction of 
baseline HOMA1-IR and treatment assignment on all-cause 
death (pint = 0.54) or cardiovascular death (pint = 0.45).
Major cardiovascular events occurred in 365 patients 
(8.5%). A twofold higher level of baseline HOMA1-IR 
was not associated with major cardiovascular events, 
either in unadjusted analysis (HR: 0.95, 95% CI: 0.86 to 
1.04, P = 0.26) or in analyses adjusted for the variables in 
model 1 (adjusted HR: 0.94, 95% CI: 0.84 to 1.05, P = 
0.29) and model 2 (adjusted HR: 1.03, 95% CI: 0.92 to 
1.15, P = 0.59). There was no interaction of baseline 
HOMA1-IR and treatment assignment on major cardio-
vascular events (pint = 0.67).
Hospitalization for heart failure occurred in 109 pa-
tients (2.5%). A twofold higher level of baseline HOMA1-
IR was associated with a lower risk of hospitalization for 
heart failure in unadjusted analysis (HR: 0.76, 95% CI: 
0.63 to 0.90, P = 0.002) and when adjusted for the var-
iables in model 1 (adjusted HR: 0.72, 95% CI: 0.59 to











P ValueN = 4303
<1.69 1.69–2.77 2.77–4.46 ‡4.46
n = 1077 n = 1075 n = 1076 n =1075
Demographics
Age, y 60.9 6 10.0 62.5 6 10.1 61.2 6 10.0 60.8 6 9.9 59.1 6 9.7 ,0.001
Sex, female 1080 (25.1) 242 (22.5) 266 (24.7) 275 (25.6) 297 (27.6) 0.05
Race ,0.001
White 2831 (65.8) 580 (53.9) 674 (62.8) 781 (72.6) 796 (74.1)
Asian 1179 (27.4) 429 (39.8) 330 (30.7) 223 (20.7) 197 (18.3)
Black 118 (2.7) 25 (2.3) 28 (2.6) 27 (2.5) 38 (3.5)
Other 174 (4.0) 43 (4.0) 42 (3.9) 45 (4.2) 44 (4.1)
Geographic region ,0.001
Europe 1370 (31.9) 283 (26.3) 320 (29.8) 368 (34.2) 399 (37.2)
North America 1226 (28.5) 235 (21.8) 283 (26.4) 344 (32.0) 364 (33.9)
Asia/Pacific 1217 (28.3) 433 (40.2) 334 (31.1) 239 (22.2) 211 (19.7)
Latin America 485 (11.3) 125 (11.6) 137 (12.8) 124 (11.5) 99 (9.2)
Medical history
Duration of type 2
diabetes, y
4.3 (1.1–9.6) 4.8 (1.3–10.3) 3.9 (0.9–9.3) 4.0 (1.1–9.0) 4.1 (1.0–8.7) 0.003
Newly diagnosed type 2
diabetes
531 (12.3) 120 (11.1) 147 (13.7) 132 (12.3) 132 (12.3) 0.36
Hypertension 3329 (77.4) 789 (73.3) 820 (76.3) 837 (77.8) 883 (82.1) ,0.001
Dyslipidemia 2684 (62.4) 583 (54.1) 683 (63.5) 697 (64.8) 721 (67.1) ,0.001
History of smoking 0.11
Current 912 (21.2) 236 (21.9) 220 (20.5) 205 (19.1) 251 (23.4)
Former 1770 (41.2) 434 (40.3) 426 (39.6) 470 (43.8) 440 (40.9)
Never 1618 (37.6) 406 (37.8) 429 (39.9) 399 (37.1) 384 (35.7)
Myocardial infarction 916 (21.3) 199 (18.5) 193 (18.0) 240 (22.3) 284 (26.4) ,0.001
Coronary artery bypass
grafting
285 (6.6) 60 (5.6) 48 (4.5) 86 (8.0) 91 (8.5) ,0.001
Percutaneous coronary
intervention
747 (17.4) 145 (13.5) 157 (14.6) 209 (19.4) 236 (22.0) ,0.001
Stroke 200 (4.6) 47 (4.4) 52 (4.8) 45 (4.2) 56 (5.2) 0.67
Peripheral vascular disease 345 (8.0) 85 (7.9) 72 (6.7) 89 (8.3) 99 (9.2) 0.19
Congestive heart failure 407 (9.5) 94 (8.7) 92 (8.6) 93 (8.6) 128 (11.9) 0.02
Clinical findings
BMI, kg/m2 28.4 (25.4–31.9) 25.9 (23.4–28.8) 27.8 (25.4–30.8) 29.2 (26.6–32.4) 31.1 (27.8–34.9) ,0.001
Systolic blood pressure,
mm Hg
128 6 17 127 6 18 127 6 18 128 6 17 129 6 17 0.04
Diastolic blood pressure,
mm Hg
76 6 10 75 6 10 76 6 10 77 6 10 77 6 10 ,0.001
Heart rate, bpm 70 6 11 70 6 11 70 6 11 70 6 11 72 6 11 ,0.001
ACS index event ,0.001
STEMI 1708 (39.7) 463 (43.0) 456 (42.4) 421 (39.1) 368 (34.3)
NSTEMI 1591 (37.0) 389 (36.1) 394 (36.7) 384 (35.7) 424 (39.5)




3333 (77.5) 829 (70.1) 825 (76.7) 845 (78.5) 834 (77.7) 0.77
Percutaneous coronary
intervention
3116 (72.5) 767 (71.4) 768 (71.4) 790 (73.4) 791 (73.7) 0.46




29 6 14 30 6 14 29 6 14 30 6 15 29 6 15 0.57
Medications
Aspirin 4120 (95.7) 1038 (96.4) 1033 (96.1) 1028 (95.5) 1021 (95.0) 0.38
Other antiplatelet agents 3836 (89.1) 959 (89.0) 967 (90.0) 960 (89.2) 950 (88.4) 0.70
Statins 4030 (93.7) 991 (92.0) 1013 (94.2) 1020 (94.8) 1006 (93.6) 0.049
Beta-blockers 3603 (83.7) 882 (81.9) 892 (83.0) 892 (82.9) 937 (87.2) 0.005
Renin-angiotensin system
inhibitors
3555 (82.6) 846 (78.6) 898 (83.5) 910 (84.6) 901 (83.8) ,0.001
(Continued)
the prognosis of patients with type 2 diabetes and ACS
who are not treated with exogenous insulin. Neither the
baseline level of HOMA-IR, nor the change in HOMA-IR
from baseline to month 3 under treatment with aleglitazar
or placebo, was related to clinical outcomes in fully ad-
justed models.
HOMA-IR has been established as an easily mea-
surable surrogate marker of insulin resistance. Although
the glucose clamp technique or the IV glucose tolerance
test represents gold-standard measures of insulin
sensitivity, measurements of fasting glucose and insulin
levels may be particularly useful in broad clinical appli-
cations (8, 9, 24). Moreover, HOMA-IR has been rec-
ognized as an independent predictor for the development
of type 2 diabetes, for the progression of the metabolic
syndrome (25, 26), and for the risk of cardiovascular
events among patients with prediabetes (10–13). In that
context, HOMA-IR has been shown to have incremental
predictive value above glucose or insulin measurements
alone (14, 27).
Table 2. HOMA-IR at Baseline and Month 3 and Change in HOMA-IR From Baseline to Month 3
Baseline Month 3 Change (From Baseline to Month 3)
Median (IQR) Median (IQR) Median (IQR)
HOMA1-IR
All 2.72 (1.68 to 4.34) 2.14 (1.26 to 3.62) 20.42 (–1.53 to 0.52)a
Aleglitazar 2.75 (1.67 to 4.33) 1.61 (1.02 to 2.68) 20.94 (–2.14 to –0.16)a,b
Placebo 2.69 (1.70 to 4.38) 2.86 (1.75 to 4.54) 0.13 (–0.77 to 1.14)a
HOMA2-IR
All 1.40 (0.90 to 2.20) 1.20 (0.80 to 1.90) 20.20 (–0.70 to 0.30)a
Aleglitazar 1.40 (0.90 to 2.20) 1.00 (0.60 to 1.50) 20.40 (–0.90 to 0.10)a,b
Placebo 1.40 (0.90 to 2.20) 1.50 (1.00 to 2.30) 0.10 (–0.30 to 0.50)a
aP , 0.001 Wilcoxon Signed-Rank test for baseline vs month 3.
bP , 0.001 Wilcoxon Rank-Sum test (treatment vs placebo for change).











P ValueN = 4303
<1.69 1.69–2.77 2.77–4.46 ‡4.46
n = 1077 n = 1075 n = 1076 n =1075
Diuretics 1215 (28.2) 258 (24.0) 303 (28.2) 324 (30.1) 330 (30.7) 0.002
Biguanides 3178 (73.9) 793 (73.6) 806 (75.0) 755 (70.2) 824 (76.7) 0.005




7.2 (6.1–8.8) 6.3 (5.4–7.3) 6.9 (6.0–8.1) 7.5 (6.4–9.0) 8.7 (7.2–11.0) —
Fasting plasma insulin,
pmol/L
59.9 (39.0–91.2) 29.1 (22.0–36.9) 51.2 (42.6–60.2) 73.9 (60.6–87.1) 127.1 (97.2–174.5) —
HOMA2-IR 1.5 (0.9–2.2) 0.7 (0.5–0.8) 1.2 (1.1–1.4) 1.8 (1.6–2.0) 3.2 (2.6–4.2) —
HOMA-B 45.5 (25.7–77.6) 28.5 (17.7–46.7) 42.1 (26.8–64.5) 52.8 (31.5–80.2) 73.3 (40.1–122.1) —
HOMA2-B 56.9 (35.6–84.7) 43.5 (29.8–63.3) 54.9 (36.6–77.6) 62.3 (38.9–88.2) 74.1 (44.0–115.4) —
Glycated hemoglobin, % 7.5 6 1.5 7.2 6 1.4 7.4 6 1.5 7.5 6 1.5 7.9 6 1.6 ,0.001
Hemoglobin, g/L 13.8 6 1.5 13.5 6 1.5 13.7 6 1.4 13.9 6 1.5 14.0 6 1.5 ,0.001
eGFR (MDRD),
mL/min/1.73m2
78 (65–90) 77 (65–90) 77 (64–90) 78 (65–91) 78 (64–91) 0.77
LDL cholesterol, mmol/L 2.05 6 0.80 2.05 6 0.81 2.04 6 0.78 2.04 6 0.80 2.07 6 0.79 0.80
HDL cholesterol, mmol/L 1.09 6 0.28 1.14 6 0.31 1.08 6 0.28 1.07 6 0.26 1.05 6 0.25 ,0.001
Triglycerides, mmol/L 1.49 (1.13–2.00) 1.31 (0.97–1.65) 1.43 (1.10–1.91) 1.56 (1.19–2.07) 1.74 (1.31–2.34) ,0.001
Creatine kinase, U/L 70 (49–102) 68 (48–98) 70 (50–99) 70 (49–102) 74 (51–113) ,0.001
hs-CRP, nmol/L 21.4 (9.1–55.5) 16.9 (7.3–48.5) 18.4 (8.5–47.5) 22.7 (10.3–58.8) 27.9 (11.6–65.5) ,0.001
NT-proBNP, pg/mL 359 (136–887) 542 (206–1274) 396 (158–945) 350 (120–803) 230 (94–594) ,0.001
Values are reported as mean 6 SD, median (IQR), or frequencies (percentages). Renin-angiotensin system inhibitors include angiotensin converting
enzyme inhibitors and receptor blockers.
Abbreviations: BMI, body mass index; HDL high-density lipoprotein; HOMA-B, homeostasis model assessment of b cell function; LDL low-density li-
poprotein; MDRD, Modification of Diet in Renal Disease; NSTEMI, non-ST segment elevation myocardial infarction; STEMI, ST segment elevation
myocardial infarction; UA, unstable angina.







HR (95% CI) P Value
Adjusted
Model 1
HR (95% CI) P Value
Adjusted
Model 2
HR (95% CI) P Value
Baseline HOMA1-IR





4303 365 (8.5) 0.95 (0.86–1.04) 0.26 0.94 (0.84–1.05) 0.29 1.03 (0.92–1.15) 0.59
Death from cardiovascular
cause
4303 110 (2.6) 0.82 (0.68–0.97) 0.02 0.83 (0.68–1.02) 0.07 1.05 (0.85–1.29) 0.66
Nonfatal myocardial
infarction
4303 232 (5.4) 0.98 (0.87–1.10) 0.74 0.97 (0.84–1.11) 0.64 1.01 (0.88–1.16) 0.89
Nonfatal stroke 4303 48 (1.1) 1.06 (0.82–1.38) 0.66 1.14 (0.85–1.53) 0.39 1.22 (0.90–1.64) 0.20
Baseline HOMA2-IR





4299 364 (8.5) 0.91 (0.82–1.02) 0.09 0.92 (0.81–1.04) 0.16 1.01 (0.90–1.15) 0.82
Death from cardiovascular
cause
4299 109 (2.5) 0.75 (0.62–0.91) 0.004 0.77 (0.61–0.96) 0.02 1.00 (0.79–1.25) 0.98
Nonfatal myocardial
infarction
4299 232 (5.4) 0.97 (0.85–1.11) 0.21 0.97 (0.83–1.13) 0.70 1.02 (0.87–1.19) 0.81
Nonfatal stroke 4299 48 (1.1) 0.98 (0.73–1.31) 0.88 1.03 (0.74–1.44) 0.86 1.11 (0.79–1.55) 0.56
Baseline HOMA2-B 0.86 (0.70–1.05)





4299 364 (8.5) 0.92 (0.83–1.02) 0.12 0.98 (0.86–1.12) 0.75 1.03 (0.91–1.18) 0.61
Death from cardiovascular
cause
4299 109 (2.5) 0.84 (0.70–1.01) 0.07 0.87 (0.69–1.10) 0.25 1.00 (0.79–1.26) 0.98
Nonfatal myocardial
infarction
4299 232 (5.4) 0.99 (0.86–1.13) 0.83 1.08 (0.92–1.27) 0.37 1.11 (0.94–1.30) 0.23
Nonfatal stroke 4299 48 (1.1) 0.79 (0.60–1.04) 0.09 0.66 (0.45–0.96) 0.03 0.69 (0.47–0.998) 0.049
Change in HOMA1-IR





3568 229 (6.4) 1.05 (0.93–1.19) 0.42 1.04 (0.91–1.20) 0.55 1.03 (0.89–1.18) 0.72
Death from cardiovascular
cause
3568 62 (1.7) 0.91 (0.72–1.14) 0.40 0.87 (0.67–1.14) 0.32 0.82 (0.64–1.07) 0.14
Nonfatal myocardial
infarction
3568 150 (4.2) 1.09 (0.93–1.26) 0.29 1.08 (0.90–1.28) 0.41 1.07 (0.90–1.27) 0.47
Nonfatal stroke 3568 31 (0.9) 1.23 (0.88–1.70) 0.23 1.24 (0.85–1.80) 0.27 1.22 (0.84–1.77) 0.29
Change in HOMA2-IR





3564 225 (6.3) 1.03 (0.89–1.19) 0.69 1.02 (0.86–1.20) 0.83 1.00 (0.85–1.18) 0.99
Death from cardiovascular
cause
3564 62 (1.7) 0.91 (0.69–1.19) 0.49 0.89 (0.66–1.21) 0.46 0.84 (0.63–1.11) 0.22
Nonfatal myocardial
infarction
3564 147 (4.1) 1.04 (0.87–1.25) 0.66 1.02 (0.83–1.26) 0.83 1.01 (0.83–1.24) 0.90
Nonfatal stroke 3564 31 (0.9) 1.31 (0.89–1.92) 0.17 1.34 (0.87–2.05) 0.19 1.32 (0.86–2.01) 0.21
Change in HOMA2-B





3564 225 (6.3) 0.90 (0.76–1.08) 0.24 0.90 (0.76–1.07) 0.24 0.89 (0.75–1.05) 0.17
(Continued)
However, the literature provides no consensus on
whether the degree of insulin resistance predicts cardio-
vascular events among patients with established type 2
diabetes, with or without established cardiovascular dis-
ease (11, 14, 15), and there has been no prior data on this
question regarding patients with type 2 diabetes and ACS.
The present analysis indicates no direct association of
insulin resistance with prognosis in such patients. More-
over, the findings were consistent in the placebo and the
aleglitazar group of the trial, and there was no signifi-
cant interaction of treatment assignment and baseline
HOMA-IR on outcomes.
Similarly, the change in HOMA-IR from baseline to
month 3 had no association with subsequent outcomes.
Figure 1. Kaplan-Meier estimates for all-cause mortality according to HOMA1-IR quartiles. Q, quartile.







HR (95% CI) P Value
Adjusted
Model 1
HR (95% CI) P Value
Adjusted
Model 2
HR (95% CI) P Value
Death from cardiovascular
cause
3564 62 (1.7) 0.85 (0.62–1.16) 0.31 0.82 (0.59–1.12) 0.21 0.77 (0.57–1.05) 0.10
Nonfatal myocardial
infarction
3564 147 (4.1) 0.90 (0.73–1.12) 0.31 0.90 (0.72–1.12) 0.33 0.89 (0.72–1.10) 0.29
Nonfatal stroke 3564 31 (0.9) 1.22 (0.79–1.88) 0.36 1.39 (0.85–2.28) 0.18 1.38 (0.84–2.25) 0.20
Values are reported as numbers and percentages. Log2 transformation was applied for HOMA1-IR, HOMA2-IR, and HOMA2-B. Therefore, HRs are for
a doubling of the variable in question. The following variables were included in Cox regression model 1: age, sex, race, body mass index, smoking,
hypertension, prior coronary artery disease, prior congestive heart failure, diabetes duration prior to randomization, time from ACS event to ran-
domization, glycated hemoglobin, log2-eGFR, log2 hs-CRP, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, log2 triglycerides,
biguanides, sulfonylureas, incretins, statins, beta-blockers, renin angiotensin blockers, calcium channel blockers, and treatment assignment (aleglitazar vs
placebo); theywere stratified by ACS index event and presence or absence of reperfusion therapy. The following variableswere included in Cox regression
model 2: variables of model 1 with addition of log2 NT-proBNP.
On average, HOMA-IR increased slightly in the placebo
group and declined substantially in the aleglitazar group,
with a large range of response in each group. Association
of change in HOMA-IR with outcomes was absent in
both groups. This may explain, at least in part, the failure
of aleglitazar to reduce cardiovascular events in diabetic
patients with established cardiovascular disease despite a
substantial reduction in HOMA-IR (21, 28).
The immediate period following ACS may be charac-
terized by stress hyperglycemia that can transiently per-
turb measurements of glucose and HOMA-IR without
reflecting the steady-state level of insulin resistance. Stress
hyperglycemia ordinarily resolves within 3 to 4 days
following ACS (29–31). In the AleCardio trial, patients
were randomized no sooner than hospital discharge and as
late as 12 weeks following ACS. We found no association
of baseline HOMA-IR with the time from ACS to ran-
domization; therefore, the baselinemeasurement ofHOMA-
IR in the present analysis is presumed to reflect a stable
glucometabolic state.
Surprisingly, our unadjusted analysis showed that
HOMA-IR was inversely related to all-cause mortality,
cardiovascular mortality, and hospitalization for heart
failure at amedian follow-up of 2.0 years. Adjustment for
24 baseline variables had only a minor effect on this
association. However, after additional adjustment for
NT-proBNP, all association of HOMA-IR with death,
cardiovascular death, or hospitalization for heart failure
was nullified. We explored the potential reasons why
adjustment for NT-proBNP influenced the relationship
of HOMA-IR with these outcomes.
An inverse relation between HOMA-IR and levels of
natriuretic peptides has been observed previously in
patients with diabetes and heart failure (16, 17), in
Framingham Offspring Study participants without overt
heart failure (32), in elderly adults (18), and in subjects
free of cardiovascular disease in the Multi-Ethnic Study
of Atherosclerosis (33). Similarly, we found that increasing
quartiles of HOMA-IR were associated with decreasing
levels of NT-proBNP. This inverse relationship is most
likely due to an interplay between adipose tissue and
natriuretic peptides. Natriuretic peptides promote lipoly-
sis, leading to decreased body weight and consecutively
decreased insulin resistance (17, 34, 35). Thus, patients
with lower HOMA-IR may have been more likely to have
mild or subclinical heart failure, reflected by higher levels
of NT-proBNP and accompanied by an increased risk of
death or hospitalization due to heart failure. Moreover,
patients in the lowest quartile ofHOMA-IR had the longest
duration of diabetes and the lowest percentage of newly
diagnosed diabetes. Long-standing diabetes is more likely
to lead to b cell failure and lower fasting insulin levels,
finally resulting in lower HOMA-IR. At the same time,
long-standing diabetes is more likely to be accompanied
by subclinical heart failure, reflected by higher levels
of NT-proBNP, associated with higher morbidity and
mortality (36).
Conversely, adipose tissue promotes catabolism of
natriuretic peptides (37, 38). Across increasing quartiles
of HOMA-IR, we observed a progressive increase in body
mass index and thus adipose tissue mass and decreasing
levels of NT-proBNP, but an increasing prevalence of
traditional coronary risk factors such as hypertension
and dyslipidemia, and of prior myocardial infarction or
coronary revascularization. Thus, patients with higher
HOMA-IR may have had increased atherosclerotic risk
despite lower levels of NT-proBNP. In aggregate, these
mechanisms may explain the inverse relationship of
HOMA-IR and NT-proBNP and the overall neutral




HR (95% CI) P Value
Adjusted Model 2
HR (95% CI) P Value
Baseline NT-proBNP
Death from any cause 1.65 (1.51–1.81) ,0.001 1.57 (1.41–1.76) ,0.001
Cardiovascular events (incident cardiovascular
death, myocardial infarction, and stroke)
1.31 (1.24–1.39) ,0.001 1.29 (1.20–1.39) ,0.001
Death from cardiovascular cause 1.76 (1.58–1.95) ,0.001 1.80 (1.57–2.07) ,0.001
Nonfatal myocardial infarction 1.17 (1.09–1.26) ,0.001 1.13 (1.03–1.23) 0.008
Nonfatal stroke 1.24 (1.06–1.46) 0.008 1.22 (1.00–1.48) 0.045
Change in NT-proBNP
Death from any cause 1.38 (1.16–1.65) ,0.001 1.50 (1.30–1.72) ,0.001
Cardiovascular events (incident cardiovascular
death, myocardial infarction, and stroke)
1.27 (1.13–1.43) ,0.001 1.23 (1.12–1.35) ,0.001
Death from cardiovascular cause 1.47 (1.18–1.83) ,0.001 1.77 (1.47–2.12) ,0.001
Nonfatal myocardial infarction 1.23 (1.06–1.43) 0.008 1.11 (1.00–1.24) 0.08
Nonfatal stroke 1.01 (0.72–1.42) 0.97 1.14 (0.89–1.47) 0.30
HRs are for a doubling of baseline NT-proBNP.
in nearly all laboratories, are not independent predictors of
prognosis in these patients, and that the change in HOMA-
IR under treatment with an insulin-sensitizing agent is not
related to outcomes. PPAR agonists exert a multitude of
effects, among which insulin sensitization is only one.
Nonetheless, the findings of the current analysis and other
investigations (21, 28) raise some doubt whether insulin
resistance or hyperinsulinemiawill prove to be a valid target
of therapy in patients with established type 2 diabetes and
coronary heart disease.
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versityMedicine, Campus Benjamin Franklin, Berlin, Germany.
E-mail: barbara-elisabeth.staehli@charite.de.
Disclosure Summary: TheAleCardio trialwas fundedbyF.
Hoffmann-La Roche (Basel, Switzerland). B.E.S. received re-
search grants from the Gottfried and Julia Bangerter-Rhyner
Foundation, the Novartis Foundation for Medical-Biomedical
Research, and the Swiss National Science Foundation. J.B.B.
received research grants from AstraZeneca, Boehringer-
Ingelheim, Bristol-Myers Squibb, Eli Lilly, GI Dynamics, Intarcia,
Johnson & Johnson, Lexicon, Medtronic, Novo Nordisk,
Orexigen, Sanofi, ScionNeuroStim,Takeda, andTheracos, has
ownership interest in PhaseBio, and is a consultant/advisory
board member of Adocia, AstraZeneca, Dance Biopharm, Eli
Lilly, Elycylex, F. Hoffman-LaRoche, GI Dynamics, Lexicon,
Merck, Metavention, Novo Nordisk, Orexigen, PhaseBio,
Quest, Takeda, and vTv Therapeutics. K.M. is employed by
Roche and Vicore Pharma. B.N. received research grants from
Abbvie, Dr. Reddy’s Laboratories, Janssen, Roche, and Servier
and honoraria from Abbott, AstraZeneca, Novartis, Pfizer,
Roche, and Servier. S.J.N. received research grants from
Anthera,Amgen,AstraZeneca,Cerenis, Eli Lilly, F.Hoffmann-
LaRoche, InfraReDx, LipoScience, Novartis, Resverlogix, and
Sanofi-Regeneron and is a consultant/advisory board member
of Abbott, Amgen, AstraZeneca, Atheronova, Boehringer
Ingelheim, CSL Behring, Esperion, LipoScience, Merck,
Novartis, Omthera, Pfizer Roche, Sanofi-Aventis, and Takeda.
L.R. received research grants from AFA Insurance Company,
Bayer AG, Karolinska Institutet Funds, Roche, the Swedish
Diabetes Association, and the SwedishHeart Lung Foundation
and honoraria from AstraZeneca, Bristol-Myers Squibb,
Roche, and Sanofi-Aventis. A.S. is employed by F. Hoffmann-
LaRoche andhasownership interest in F.Hoffmann-LaRoche.
H.W. received honoraria fromAstraZeneca, Roche, and Pfizer.
A.W. is employed by F. Hoffmann-La Roche. A.M.L. and
D.E.G. received research grants from F. Hoffmann-La Roche.
J.-C.T. received research grants from Amarin, Eli Lilly, Isis,
Merck,Pfizer,Roche, Sanofi-Aventis, Servier, andDalCorand
honoraria fromServier.G.G.S. received research support from
Cerenis, Resverlogix, TheMedicinesCompany, F.Hoffmann-
La Roche, and Sanofi. The remaining authors have nothing
to disclose.
relationship of HOMA-IR to mortality and heart failure 
hospitalization after accounting for levels of NT-proBNP.
We found no association of HOMA-IR with the risk 
of nonfatal ischemic cardiovascular events. Despite a 
relatively large number of nonfatal myocardial infarc-
tions (n = 232), there was no association of HOMA-IR 
with these events in either unadjusted or adjusted anal-
ysis. This suggests that once patients have established 
type 2 diabetes and coronary heart disease, the degree of 
insulin resistance may not determine the risk of future 
myocardial infarction. Inferences regarding nonfatal stroke 
are more difficult to draw because of the smaller number of 
events (n = 48).
Strengths of the current analysis include the use of a 
large, global data set, high utilization of contemporary, 
evidence-based pharmacologic and procedural treat-
ments for ACS, and a broad range of baseline HOMA-
IR values and the change in HOMA-IR with treatment, 
allowing robust analyses of the relationships of base-
line and on-treatment HOMA-IR with outcomes. In 
addition, principal findings were confirmed in sensi-
tivity analyses using HOMA2-IR, excluding patients 
on sulfonylureas, and investigating treatment groups 
separately.
Several limitations also warrant consideration. First, 
this study is a post hoc analysis of the AleCardio trial 
with the limitations inherent to such a design. Second, 
AleCardio was not conceived as a heart failure trial, and 
measures of left ventricular ejection fraction were not 
available systematically in this patient cohort. Third, 
fasting insulin incorporated into the HOMA-IR model 
reflects not only insulin resistance, but also insulin se-
cretion and clearance, and as a proxy for fasting insulin, 
HOMA-IR cannot distinguish between insulin resistance 
and circulating insulin itself. Fourth, the predictive value 
of the HOMA-IR was investigated in diabetic patients 
not treated with insulin, as exogenous insulin would have 
influenced the value of HOMA-IR. Therefore, the present 
findings may not apply to patients treated with insulin. 
Further, in comparison with some other studies (14), 
HOMA-IR in the present cohort is lower; the differences 
may be due to a shorter duration of diabetes among 
patients in AleCardio and the inclusion of patients with 
newly diagnosed diabetes at the time of ACS. In addition, 
although we used a comprehensive group of adjustment 
variables, we cannot exclude the possibility of residual 
confounding by factors not incorporated into the mul-
tivariate models.
In conclusion, insulin resistance as estimated by the 
HOMA-IR is not an independent predictor of mortality 
and cardiovascular events in patients with type 2 diabetes 
and recent ACS. Our study adds to the literature that 
measurements of glucose and insulin, tests that are available
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